Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is among the 12 Best American Penny Stocks to Buy Right Now. Citizens raised its price target on TSHA from $6 to $8 with a Market Outperform rating. The company finalized its REVEAL pivotal trial for Rett syndrome treatment, giving it a competitive advantage.

Citizens praised TSHA for finalizing its pivotal protocol and statistical analysis plan, planning to start the trial in Q4 2025. The company adhered to new FDA guidelines and maintained communication with the agency despite leadership changes, reducing regulatory risks. Probability of success estimate for the Rett Syndrome program increased from 33% to 55%.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company specializing in AAV-based gene therapies for central nervous system monogenic diseases. While TSHA offers investment potential, other AI stocks may have greater upside with less downside risk. For an undervalued AI stock with growth potential, consider the best short-term AI stock.

For more stock recommendations, check out 10 Stocks Under $20 to Buy According to Analysts and 12 Best Performing Stocks in the Last 3 Months. Disclosure: None. Source: Insider Monkey.

Read more at Yahoo Finance: Citizens Lifts Price Target for Taysha Gene Therapies (TSHA)